Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
Apr 18, 2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Apr 18, 2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael
Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas
Brügge D, Putora P, Hundsberger T, Weder P, van Leyen K, Plasswilm L (2011). Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas.
Mar 31, 2011Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas
Mar 31, 2011SASRO 2011
Brügge Detlef, Putora Paul Martin, Hundsberger Thomas, Weder Patrik, van Leyen Karin, Plasswilm Ludwig
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
Mar 9, 2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Mar 9, 2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.
Feb 18, 2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Feb 18, 2011Ann Oncol 2011; 22:2201-2207
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
Feb 14, 2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Feb 14, 2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
Jan 4, 2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Jan 4, 2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
Knauer M, Cardoso F, Wesseling J, Bedard P, Linn S, Rutgers E, van 't Veer L. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010; 103:1788-93.
Nov 16, 2010Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
Nov 16, 2010Br J Cancer 2010; 103:1788-93
Knauer Michael, Cardoso F, Wesseling J, Bedard P L, Linn S C, Rutgers E J T, van 't Veer L J
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Sun Z, Ribi K, Aldridge J, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2010
Nov 3, 2010Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Nov 3, 2010Breast Cancer Res Treat 2010
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Sun Zhuoxin, Ribi Karin, Aldridge Julie, Bernhard Jürg
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2010; 125:145-56.
Nov 3, 2010Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
Nov 3, 2010Breast Cancer Res Treat 2010; 125:145-56
von Minckwitz Gunter, Gerber Bernd, du Bois Andreas, Huober Jens, Hanusch Claus, Konecny Gottfried, Fett Werner, Stickeler Elmar, Harbeck Nadia, Müller Volkmar, Jackisch Christian, Hilfrich Jörn, Mehta Keyur, Untch Michael, Nüesch Eveline, Loibl Sibylle, Kaufmann Manfred, Kümmel Sherko, Fasching Peter A, Eiermann Wolfgang, Blohmer Jens-Uwe, Costa Serban Dan, Jüni Peter
[Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark--a comparative Study"]
Thürlimann B. [Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark--a comparative Study"]. Praxis (Bern 1994) 2010; 99:1217-8.
Oct 6, 2010[Commentary from the viewpoint of an advocate. "Breast cancer mortality in organized mammography screening in Denmark--a comparative Study"]
Oct 6, 2010Praxis (Bern 1994) 2010; 99:1217-8
Thürlimann Beat
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Mouridsen H, Thürlimann B, Robidoux A, Llombart-Cussac A, Gligorov J, Doughty J, Blackwell K, Beckmann M, Lønning P, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther 2010; 10:1825-1836.
Sep 30, 2010Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Sep 30, 2010Expert Rev Anticancer Ther 2010; 10:1825-1836
Mouridsen Henning T, Thürlimann Beat, Robidoux Andre, Llombart-Cussac Antonio, Gligorov Joseph, Doughty Julie, Blackwell Kimberly, Beckmann Matthias W, Lønning Per, Gnant Michael
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Witzel I, Untch M, Roller M, Eulenburg C, Barinoff J, Hilfrich J, Just M, Latos K, Tesch H, Lantzsch T, Hauschild M, Henschen S, Hanusch C, Huober J, Mundhenke C, von Minckwitz G, Loibl S, Müller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010; 123:437-45.
Sep 1, 2010Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Sep 1, 2010Breast Cancer Res Treat 2010; 123:437-45
Witzel Isabell, Untch Michael, Roller Marc, Eulenburg Christine Zu, Barinoff Jana, Hilfrich Jörn, Just Marianne, Latos Kunibert, Tesch Hans, Lantzsch Tilmann, Hauschild Maik, Henschen Stephan, Hanusch Claus, Huober Jens, Mundhenke Christoph, von Minckwitz Gunter, Loibl Sibylle, Müller Volkmar
What is the value of the 21-gene recurrence score?
Brauchli P, Thürlimann B, Crowe S, Herrmann R. What is the value of the 21-gene recurrence score?. J Clin Oncol 2010; 28:e671-2.
Aug 30, 2010What is the value of the 21-gene recurrence score?
Aug 30, 2010J Clin Oncol 2010; 28:e671-2
Brauchli Peter, Thürlimann Beat, Crowe Susanne N, Herrmann Richard
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
du Bois A, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Kurzeder C, Weber B, Herrstedt J, Hardy-Bessard A, Müller H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28:4162-9.
Aug 23, 2010Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
Aug 23, 2010J Clin Oncol 2010; 28:4162-9
du Bois Andreas, Jelic Svetislav, Pujade-Lauraine Eric, Burges Alexander, Pfisterer Jacobus, Gropp Martina, Staehle Anne, Wimberger Pauline, Jackisch Christian, Kurzeder Christian, Weber Béatrice, Herrstedt Jørn, Hardy-Bessard Anne-Claire, Müller Hans-Helge, Harter Philipp, Kristensen Gunnar, Joly Florence, Huober Jens, Avall-Lundqvist Elisabeth, Sehouli Jalid
Predictors of state-of-the-art management of early breast cancer in Switzerland
Ess S, Jörger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
Aug 12, 2010Predictors of state-of-the-art management of early breast cancer in Switzerland
Aug 12, 2010Ann Oncol 2010; 22:618-24
Ess S, Jörger Markus, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann Beat
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Huober J, Mehta K, Darb-Esfahani S, Högel B, Thomssen C, Hauschild M, Khandan F, Belau A, Zahm D, Weiss E, Tesch H, Denkert C, von Minckwitz G, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133-40.
Aug 10, 2010Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Aug 10, 2010Breast Cancer Res Treat 2010; 124:133-40
Huober Jens, Mehta Keyur, Darb-Esfahani Silvia, Högel Bernhard, Thomssen Christoph, Hauschild Maik, Khandan Fariba, Belau Antje, Zahm Dirk Michael, Weiss Erich, Tesch Hans, Denkert Carsten, von Minckwitz Gunter, Loibl Sibylle
New Developments in Breast Cancer Therapy Presented at ASCO 2010
Müllera V, Dubsky P, Fehm T, Fitzal F, Huober J, Schmidt M, Steger G. New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast Care (Basel) 2010; 5:266-271.
Aug 9, 2010New Developments in Breast Cancer Therapy Presented at ASCO 2010
Aug 9, 2010Breast Care (Basel) 2010; 5:266-271
Müllera Volkmar, Dubsky Peter, Fehm Tanja, Fitzal Florian, Huober Jens, Schmidt Marcus, Steger Günther
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010
Aug 4, 2010Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Aug 4, 2010Cancer Chemother Pharmacol 2010
Jörger Markus, Templeton Arnoud, Köberle Dieter, Engler H, Riesen W F, Thürlimann Beat
Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
Jörger M, Riesen W, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010
Jul 28, 2010Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
Jul 28, 2010J Oncol Pharm Pract 2010
Jörger Markus, Riesen W F, Thürlimann Beat
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
von Moos R, Caspar C, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. Onkologie 2010; 33:447-50.
Jul 6, 2010Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
Jul 6, 2010Onkologie 2010; 33:447-50
von Moos Roger, Caspar Clemens B, Steiner Rolf, Angst Rahel, Inauen Roman, Schmieding Kerstin, Thürlimann Beat